Text size A - A+


Besivance Eye Drops
(Besifloxacin 0.6% Ophthalmic Suspension)

Key Features & Benefits

  • BESIVANCE (besifloxacin ophthalmic suspension) 0.6%, is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans *, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa *, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*

    *Efficacy for this organism was studied in fewer than 10 infections.


Active: Besifloxacin Hydrochloride USP equivalent to Besifloxacin 0.6% w/v

Inactive Ingredients: Polycabophil, mannitol, poloxamer 407, sodium chloride, edetate disodium dihydrate, sodium hydroxide and water for injection

Preservative Added: Benzalkonium chloride 0.01%


Besivance Eye Drops are indicated for the treatment of bacterial conjunctivitis caused by susceptible organisms.

Dosage & Administration

Invert the closed bottle and shake once before use.

Instill one drop in the affected eye(s) 3 times a day, four to twelve hours apart for 7 days.

Important Risk Information

  • Besivance is for topical ophthalmic use only, and should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.

  • As with other anti-infectives, prolonged use of Besivance may result in overgrowth of nonsusceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.

  • Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with Besivance.

  • The most common adverse event reported in 2% of patients treated with Besivance was conjuntival redness. Other adverse events reported in patients receiving Besivance occuring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.

  • Besivance is not intended to be administered systemically. Quinolones administered systemically have been associated with hypersensitivity reactions, even following a single dose. Patients should be advised to discontinue use immediately and contact their physician at the first sign of a rash or allergic reaction.

  • Safety and effectiveness in infants below one year of age have not been established.

Besivance : Additional information

‘For Further Enquires Contact Ipca Laboratories Ph: +91 22 6210 5400 Email : ipca@ipca.com